Dare Bioscience Investor Presentation Deck
DARE-VVA1*
Proprietary tamoxifen formulation for vaginal administration for vulvar and vaginal atrophy (VVA),
a chronic condition characterized by pain during intercourse, vaginal dryness and irritation.
There are currently no FDA approved products labeled for VVA treatment in HR+ breast cancer.
Potential to be the first therapeutic specifically approved for treatment of VVA in
patients with hormone-receptor positive (HR+) breast cancer.
Approximately 3.8 million US women have a history of breast cancer; HR+ is the
most common type.²
•Localized estrogen therapy for VVA may be contraindicated for women diagnosed
with, or at risk of recurrence of, ER-positive and PR-positive breast cancer.
•VVA prevalence in postmenopausal breast cancer survivors is estimated at 42 to
70%.³
Daré is developing this novel local application of tamoxifen to mitigate the symptoms of VVA for HR+
breast cancer patients, including women currently on anti-cancer therapy.
*505(b)(2) candidate¹
1. Anticipated regulatory pathway. Daré has not had any communications with the FDA regarding the specific marketing approval requirements for DARE-VVA1.
2.American Cancer Society, Breast Cancer Facts & Figures 2019-2020, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-
3. Clinical Breast Cancer, Dec 2017: https://www.sciencedirect.com/science/article/pii/S1526820917300952
2020.pdf
44View entire presentation